TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15583956
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg budipine (t.i.d.)
Study: 10066843
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (rtPA and placebo)
Study: 2292534
Drug: Cefpodoxime proxetil
Normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefpodoxime proxetil 200 mg bd orally for 10 days
Study: 2292534
Drug: Ceftriaxone 1
Normalized name: ceftriaxone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 1 g daily im for 10 days
Study: 6789356
Drug: Pentobarbital (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentobarbital (three doses)
Study: 29741201
Drug: Fermented Papaya
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented Papaya Preparation (FPP®) 9g/day
Study: 25492830
Drug: Amiloride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride (5 mg/d, increased to 10 mg if BP control not achieved at 4 weeks)
Study: 22571202
Drug: Lenalidomide maintenance
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide maintenance therapy (10 mg per day for the first 3 months, increased to 15 mg if tolerated)
Study: 20821979
Drug: Reamberin (antioxidant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reamberin (antioxidant preparation)
Study: 1563213
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of furosemide (4 mg/hr for 8 hours after an 8 mg loading dose, total dose 40 mg)
Study: 1563213
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of furosemide (40 mg)
Study: 1563213
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of furosemide
Study: 1563213
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of furosemide
Study: 3890435
Drug: Indoprofen (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoprofen (400 mg, intravenous)
Study: 3890435
Drug: Oxicone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxicone (10 mg, intramuscular) combined with papaverine (20 mg)
Study: 3890435
Drug: Oxicone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxicone (10 mg, intramuscular)
Study: 3013766
Drug: Nadolol, 80
Normalized name: Nadolol, 80 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol, 80 mg/day plus hydrochlorothiazide 12.5 mg/day
Study: 3013766
Drug: Nadolol, 80
Normalized name: Nadolol, 80 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol, 80 mg/day plus hydrochlorothiazide 25 mg/day
Study: 3013766
Drug: Nadolol, 80
Normalized name: Nadolol, 80 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol, 80 mg/day plus hydrochlorothiazide 50 mg/day
Study: 3013766
Drug: Nadolol, 80
Normalized name: Nadolol, 80 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol, 80 mg/day plus hydrochlorothiazide 12.5 mg/day for 6 weeks
Study: 8884536
Drug: Nasal administration
Normalized name: Novel Influenza-H1N1-09, live virus for nasal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal administration of bromocriptine (0.8 mg)
Study: 8884536
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of bromocriptine (2.5 mg)
Study: 27195814
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment group (SBP target <120 mm Hg, n=1317)
Study: 27195814
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment group (SBP target <140 mm Hg, n=1319)
Study: 22365565
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion with remifentanil
Study: 12811363
Drug: Gemfibrozil (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil (1200 mg/d)
Study: 11064623
Drug: 1% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% ropivacaine plus hyaluronidase 300 IU ml-1
Study: 11064623
Drug: 0.5% bupivacaine/2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine/2% lidocaine plus 50 IU ml-1 hyaluronidase
Study: 8650942
Drug: Mildly protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mildly protein restricted diet (0.7 g/kg/day)
Study: 8650942
Drug: Normal protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal protein diet (1.2 g/kg/day)
Study: 23394867
Drug: Steroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid treatment (S group)
Study: 23394867
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with steroid and antiviral agent (S+A group)
Study: 21459795
Drug: Conventional post-remission
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional post-remission therapy
Study: 18280811
Drug: High-activity genotype
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-activity genotype (G/G) in non-diabetic subjects
Study: 16531708
Drug: Postoperative adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative adjuvant chemotherapy (platinum-based chemotherapy or UFT)
Study: 12937238
Drug: Nutritional status
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional status in patients with low dietary protein intake (DPI < 0.8 g/kg body weight/day) and energy intake (DEI < 25 kcal/kg body weight/day)
Study: 12937238
Drug: Interventional study
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interventional study to increase daily DPI and DEI in LOW group
Study: 12937238
Drug: Adequate nutrient
Normalized name: Adequan
DrugBank: Polysulfated glycosaminoglycan (DB11538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adequate nutrient intake (DPI ≥ 0.8 g/kg body weight/day and DEI ≥ 25 kcal/kg body weight/day) in CON group
Study: 10713234
Drug: Timolol 0.5%
Normalized name: Timolol 0.5% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 0.5% gel-forming solution (Timoptol-XE(R))
Study: 9333701
Drug: Adjuvant medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant medical treatments (TNF alpha and interleukin-1 synthesis inhibitors or antibodies)
Study: 9333701
Drug: Taurolidine (local
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taurolidine (local and intravenous routes)
Study: 8324332
Drug: Cimetidine 50
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine 50 mg/kg intravenously
Study: 28029266
Drug: Hybrid hyrax
Normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid hyrax appliance anchored on mini-implants (Group B)
Study: 21920204
Drug: Methylprednisolone +
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone + levobupivacaine + saline (G-M + L)
Study: 21920204
Drug: Methylprednisolone +
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone + saline (G-M)
Study: 17056975
Drug: Patient-controlled epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled epidural analgesia (PCEA) with ropivacaine 0.125% and sufentanil 1.0 microg/mL at 14 mL/h; bolus: 5 mL; lockout time: 15 min
Study: 17056975
Drug: Patient-controlled intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled intravenous analgesia (PCIA) with morphine 2.0 mg/mL; bolus: 3 mg; lockout time: 15 min
Study: 14598938
Drug: Gemifloxacin (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemifloxacin (320 mg/day)
Study: 14598938
Drug: Trovafloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trovafloxacin (200 mg/day)
Study: 8874573
Drug: Intramuscular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular morphine 5 mg
Study: 8061845
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of spirapril once daily
Study: 8061845
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg of spirapril once daily
Study: 8061845
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg of spirapril once daily
Study: 8061845
Drug: 24 mg
Normalized name: uracil 224 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 mg of spirapril once daily
Study: 2647050
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of cefoxitin before operation
Study: 30565342
Drug: Simulated TEAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simulated TEAS combined with sertraline (group A)
Study: 30565342
Drug: Active TEAS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active TEAS combined with CBT plus sertraline (group D)
Study: 25306231
Drug: cryotherapy in
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cryotherapy in combination with burst TENS
Study: 25306231
Drug: cryotherapy in
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cryotherapy in combination with conventional TENS
Study: 17512147
Drug: Tablet A
Normalized name: tablet administration aid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet A (swelling/disintegration-type matrix tablet with hydrophobic wax and hydrophilic polymer granules)
Study: 17512147
Drug: Tablet B
Normalized name: Biaxin 4 Tablet Blister Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet B (matrix tablet consisting of hydrophilic polymer granules)
Study: 11504980
Drug: Immunological response,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunological response, higher RDI, CR to chemotherapy
Study: 9676069
Drug: Newer Antidepressants
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Newer Antidepressants (NAs)
Study: 9676069
Drug: Older Antidepressants
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Older Antidepressants (OAs) - TCA group
Study: 9676069
Drug: Older Antidepressants
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Older Antidepressants (OAs) - NTCA-SSRI group
Study: 9676069
Drug: Older Antidepressants
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Older Antidepressants (OAs) - SSRIs
Study: 3907843
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg BID
Study: 31876117
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate (once-monthly formulation)
Study: 26015650
Drug: Ofloxacin +
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ofloxacin + dexamethasone combination (ODC) eardrops for 15 days
Study: 24183751
Drug: Negative attitudes
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Negative attitudes toward medication
Study: 24183751
Drug: Medication side
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication side effects
Study: 17493468
Drug: Drug-Eluting Stents
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-Eluting Stents (DESs)
Study: 16490807
Drug: AST-120 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: AST-120 (3 g thrice daily for 2 days) administered 60 minutes after losartan (100 mg) under fed conditions (Treatment C)
Study: 16490807
Drug: AST-120 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: AST-120 administered 30 minutes prior to losartan (Treatment D)
Study: 16490807
Drug: AST-120 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: AST-120 administered 30 minutes after losartan (Treatment E)
Study: 16490807
Drug: Losartan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (100 mg) administered alone under fasting conditions (Treatment A)
Study: 16490807
Drug: Losartan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (100 mg) administered alone under fed conditions (Treatment B)
Study: 30369394
Drug: Timing of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timing of once-daily insulin injections
Study: 27003376
Drug: Transdiagnostic cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdiagnostic cognitive behaviour therapy (TD‐CBT)
Study: 27003376
Drug: Disorder‐specific cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disorder‐specific cognitive behaviour therapy (DS‐CBT)
Study: 10365837
Drug: Endoscopic Nd:YAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic Nd:YAG laser treatment
Study: 10365837
Drug: Intratumoural injection
Normalized name: ALCOHOL 80 mL in 100 mL INTRATUMOR LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratumoural injection of 98% alcohol
Study: 7736318
Drug: Calcitriol treatment
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcitriol treatment (0.5 microgram/day) for 1 month
Study: 7736318
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro CTR treatment (10(‐7) M) of PBMC
Study: 7736318
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro CTR treatment (10(‐7) M) for 48 hours in PBMC from HD patients
Study: 7736318
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro CTR treatment (10(‐11) and 10(‐9) M)
Study: 7736318
Drug: Calcitriol treatment
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcitriol treatment effect on serum levels
Study: 2407164
Drug: PCA infusion
Normalized name: PCA Infusion Set 80"
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA infusion (Abbott Lifecare)
Study: 2407164
Drug: Traditional postoperative
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional postoperative analgesia (intramuscular or intravenous methods)
Study: 30399184
Drug: Whole of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole of service intervention that diverted people away from hospital and into stepped care psychological therapy clinics
Study: 22971472
Drug: Comparator (COMP,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator (COMP, 100% probability of receiving active medication)
Study: 22971472
Drug: Placebo-controlled (PC,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-controlled (PC, 50% probability of receiving active medication)
Study: 22971472
Drug: Both COMP
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both COMP and PC conditions (active medication)
Study: 20429673
Drug: Ospemifene (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ospemifene (daily doses)
Study: 17995971
Drug: Carvedilol, daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol, daily doses of 3 mg kg(‐1) for infants (28 days to 23 months)
Study: 12957443
Drug: Beta-blocker therapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker therapy with bucindolol
Study: 30573715
Drug: K+T+A (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: K+T+A (1 tablet of Ketorolac 10 mg plus 1 capsule of Tramadol 37.5 mg/acetaminophen 325 mg)
Study: 30573715
Drug: K (1
Normalized name: Post Baby High Waist Black (1X/2X)
Approvals — FDA: no, EMA: no, PMDA: no
Description: K (1 tablet of Ketorolac 10 mg plus 1 placebo capsule)
Study: 24619298
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sorafenib 400 mg bid with IV carboplatin (AUC 6) and IV paclitaxel 175 mg/m2 (S+C/T) every 3 weeks
Study: 17720661
Drug: Darunavir with
Normalized name: Darunavir
DrugBank: Darunavir (DB01264)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Darunavir with low-dose ritonavir (DRV/r)
Study: 15871609
Drug: Oral diclofenac
Normalized name: diclofenac Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diclofenac sodium (50 mg tablets, twice a day for 14 days)
Study: 15871609
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac (16 mg/ml, 10 drops 4 times a day for 14 days)
Study: 10624546
Drug: Sertraline (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (12 weeks treatment)
Study: 10624546
Drug: Placebo (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (12 weeks treatment)
Study: 826236
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of glucose and amino acids
Study: 31483662
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with Bevacizumab
Study: 31483662
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy without Bevacizumab
Study: 25939332
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of pregabalin 300 mg hard capsules
Study: 25939332
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of pregabalin 300 mg hard capsules
Study: 23945406
Drug: Korean red
Normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Korean red ginseng (6 g daily for 12 weeks)
Study: 22048221
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg clopidogrel + PA32540 followed by 75 mg clopidogrel + PA32540 on days 2-7
Study: 22048221
Drug: PA32540 in
Approvals — FDA: no, EMA: no, PMDA: no
Description: PA32540 in the morning + 300 mg clopidogrel 10 h later on day 1 and PA32540 in the morning + 75 mg clopidogrel 10 h later on days 2-7
Study: 22048221
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg clopidogrel + 325 mg ECASA followed by 75 mg clopidogrel + 325 mg ECASA on days 2-7
Study: 19019244
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E supplementation (50 mg/day)
Study: 2982387
Drug: etomidate 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: etomidate 0.3 mg kg‐1
Study: 2982387
Drug: thiopentone 5
Normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: thiopentone 5 mg kg‐1
Study: 31033527
Drug: Phenazopyridine 200
Normalized name: phenazopyridine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenazopyridine 200 mg on postoperative day 1
Study: 31829274
Drug: Dexmedetomidine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.4 μg/kg/h, increased by 0.2 μg/kg/h per hour up to 0.8 μg/kg/h; neonates: 0.2 μg/kg/h, increased by 0.1 μg/kg/h per hour up to 0.4 μg/kg/h)
Study: 27373542
Drug: Home insertion
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home insertion of etonogestrel implant
Study: 27373542
Drug: Office insertion
Normalized name: Office First Aid Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Office insertion of etonogestrel implant
Study: 22614150
Drug: Carbohydrate (CHO)
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate (CHO) supplementation (1 g/kg loading dose and 0.17 g/kg every 6 minutes)
Study: 22614150
Drug: Placebo (PL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PL) supplementation (equal volume of saccharin and aspartame solution)
Study: 12775025
Drug: Personalized chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized chemotherapy based on gene expression profiles
Study: 12775025
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard treatment without gene expression profiles)
Study: 11778496
Drug: M. vaccae
Approvals — FDA: no, EMA: no, PMDA: no
Description: M. vaccae + chemotherapy
Study: 11778496
Drug: Chemotherapy followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy followed by M. vaccae (Self control)
Study: 8165385
Drug: Carbidopa/levodopa (25/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbidopa/levodopa (25/100 mg and 50/200 mg)
Study: 8165385
Drug: Propoxyphene (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propoxyphene (100 mg and 200 mg)
Study: 2427838
Drug: Celiprolol 200
Normalized name: celiprolol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol 200 mg once daily for one week, followed by 400 mg once daily for the third week
Study: 2427838
Drug: Celiprolol (exact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol (exact dosage not specified during crossover phase)
Study: 22726105
Drug: Thymosin α-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymosin α-1 plus peginterferon α-2a (180 μg weekly for 48 weeks and 1.6 mg twice a week for the first 12 weeks)
Study: 22726105
Drug: Peginterferon α-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon α-2a monotherapy (180 μg weekly for 48 weeks)
Study: 19747581
Drug: 0.6 mg
Normalized name: thymol 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg oSCT
Study: 19747581
Drug: 0.8 mg
Normalized name: biotin 0.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg oSCT